– USA, MA – Morphoceuticals Inc., a TechBio company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, announced the appointment of Dr. Roger Pomerantz (MD) to its Board as an Independent Director and Chairman.
About Dr. Roger J. Pomerantz
Dr. Roger Pomerantz has led the development of 14 large and small molecule therapies, and a breakthrough microbiome therapeutic, that have all won FDA approval. He serves on the Boards of Directors for multiple life sciences companies, including Enlivex Therapeutics, Indaptus Therapeutics, 1E Therapeutics, and CollPlant. He was the President, CEO, and Chairman of Seres Therapeutics, the first publicly traded microbiome therapeutics company.
Dr. Roger Pomerantz held senior roles at multiple pharmaceutical companies, including as the Global Head of Infectious Disease at Johnson & Johnson and Head of Licensing and Acquisitions at Merck.
Dr. Roger Pomerantz holds a BA in Biochemistry and an MD, both from The Johns Hopkins University.
About Morphoceuticals
Morphoceuticals is a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease. The bioelectrome is the set of electrical communication networks within the body that bind multi-cellular collectives together for a common purpose, maintaining tissue and organ-level integrity and health. We are building an atlas of the bioelectrome using our world-first suite of model systems and proprietary AI techniques. By understanding and manipulating these networks, we aim to rewrite them for the treatment of conditions that are inadequately addressed by existing therapeutic strategies. At Morphoceuticals, we are reprogramming the software of life.
Morphoceuticals is building on the groundbreaking work of its co-founders, Michael Levin, Vannevar Bush Professor of Biology in the School of Arts and Sciences, and David Kaplan, Stern Family Endowed Professor of Engineering in the School of Engineering, both of Tufts University, who successfully demonstrated limb regeneration in an African clawed frog, becoming the first to achieve functional limb regeneration in an adult animal of a species that does not naturally regenerate complex limbs in adulthood.
The company has secured more than $15 million in seed financing, initially led by Juvenescence and Prime Movers Lab.
For more: https://www.morphoceuticals.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.